Breaking News
Get 50% Off 0
🧩 Based on my current watchlist, how should I diversify my portfolio?
Ask WarrenAI
Close

Vaccinex Inc (VCNX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.700 -0.010    -1.41%
08/08 - Closed. Currency in USD
Type:  Equity
Market:  United States
  • Volume: 6,615
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.700 - 0.880
Vaccinex 0.700 -0.010 -1.41%

Vaccinex Inc Company Profile

 
Get an in-depth profile of Vaccinex Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

25

Equity Type

ORD

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company’s lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer’s disease and has completed phase 2 study for the treatment of Huntington’s disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer. The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses. In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Contact Information

Address 1895 Mount Hope Avenue
Rochester, 14620
United States
Phone 585 271 2700
Fax 585 271 2765

Top Executives

Name Age Since Title
Maurice Zauderer 75 2001 Co-Founder, CEO, President & Director
Albert D. Friedberg 74 2001 Chairman of the Board
Mark J. Tullman - - Scientific and Clinical Advisor
Ray Dorsey - - Scientific & Clinical Advisor
Max Vasquez - - Member of Scientific & Clinical Advisory Board
Susan M. Jerian - - Scientific & Clinical Advisor
Andrew S. Feigin - - Scientific & Clinical Advisor
Jacob B. Frieberg 68 2015 Independent Lead Director
Elizabeth M. Jaffe - - Scientific & Clinical Advisor
Matilde Inglese - - Scientific & Clinical Advisor
Ramesh Ramanathan - - Scientific & Clinical Advisor
Leisha A. Emens - - Scientific & Clinical Advisor
Khurram Bashir - - Scientific and Clinical Advisor
Karl Kieburtz - - Scientific Advisor
Peter A. Calabresi - - Scientific & Clinical Advisor
Andrew D. Goodman - - Scientific & Clinical Advisor
Anthony W. Tolcher - - Scientific and Clinical Advisor
David M. Essayan - - Scientific & Clinical Advisor
Jeffrey A. Cohen - - Scientific & Clinical Advisor
Laura J. Balcer - - Scientific & Clinical Advisor
Steven L. Galetta - - Scientific & Clinical Advisor
Amita Patnaik - - Scientific & Clinical Advisor
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VCNX Comments

Write your thoughts about Vaccinex Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email